In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease ...

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms ...

Eli Lilly (LLY) stock is in focus as its Jaypirca cancer drug succeeds in a Phase 3 trial for newly diagnosed patients with ...

Eli Lilly and Company (NYSE: LLY) today announced results from the Phase 3 BRUIN CLL-313 clinical trial of Jaypirca ...

美国FDA于2025年12月3日批准了礼来公司的Jaypirca（pirtobrutinib，匹妥布替尼）扩大适应症，用于治疗既往接受过共价BTK抑制剂治疗的复发或难治性慢性淋巴细胞白血病或小淋巴细胞淋巴瘤（CLL/SLL）成人患者。此次批准将于20 ...

Jaypirca significantly improved progression-free survival in treatment-naive CLL/SLL, reducing disease progression or death risk by 80% compared to BR. The 24-month progression-free survival rate was ...

Pirtobrutinib significantly improved PFS in previously untreated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma compared with a standard chemoimmunotherapy regimen in a ...

The presentation and publication of the BRUIN CLL-314 trial followed the FDA’s December 3 decision to expand approval for ...

Jaypirca (pirtobrutinib) improved progression-free survival in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) when compared with bendamustine ...

Zanubrutinib and venetoclax combination shows an 87% 36-month PFS rate in CLL/SLL patients, regardless of del (17p)/TP53 or IGHV status. The SEQUOIA trial demonstrates durable minimal residual disease ...

The U.S. Food and Drug Administration (FDA) has granted traditional approval to Jaypirca (pirobrutinib) for the treatment of ...

Researchers said future studies could help refine the use of Jaypirca alone or in combination with other therapies as a frontline treatment. She added that they are also continuing to investigate ...